Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma.

Abstract

PURPOSE:

To report the results of ruthenium-106 plaque radiotherapy for iris malignant melanoma.

METHODS:

A retrospective study of 15 patients with pure iris melanoma treated with ruthenium-106 plaque radiotherapy from June 1998 to June 2006. The main outcome measures were tumour control and ocular complications.

RESULTS:

Of the 15 patients, 8 had biopsy-proven melanoma (6 incisional and 2 excisional biopsies). In the remaining seven patients enlargement of the lesion was documented. The median follow-up was 96 months (ranging from 14 months to 12 years). Common radiation-related complications included cataract in 9 (60%) patients, dry eyes in 3 (20%) patients and elevated intraocular pressure in 4 (27%) patients. Vision was preserved in 80% of patients. Local tumour control was obtained in all patients.

CONCLUSIONS:

Ruthenium-106 plaque radiotherapy is an effective treatment for primary malignant iris melanoma, resulting in excellent local control with preservation of vision. Main complications included cataract, dry eyes, and glaucoma.

• Authors: M Tsimpida, J Hungerford, A Arora, V Cohen
• Journal: Eye (London, England) (Eye (Lond)) Vol. 25 Issue 12 Pg. 1607-11 (Dec 2011) ISSN: 1476-5454 [Electronic] England
• PMID: 21941358 (Publication Type: Journal Article)

Chemical References

• Ruthenium Radioisotopes

Topics

• Adult
• Aged
• Aged, 80 and over
• Brachytherapy (methods)
• Female
• Follow-Up Studies
• Humans
• Intraocular Pressure (radiation effects)
• Iris Neoplasms (radiotherapy)
• Male
• Melanoma (radiotherapy)
• Middle Aged
• Retrospective Studies
• Ruthenium Radioisotopes (therapeutic use)